Esophageal Squamous Cell Carcinoma companies are dedicated to combating this specific cancer type. Through research and development, they provide targeted therapies and interventions to address esophageal squamous cell carcinoma, contributing to advancements in oncology and personalized cancer treatment.
BeiGene receives US FDA Breakthrough Therapy Designation for tislelizumab (an anti-PD-1 monoclonal antibody) for the treatment of locally advanced unresectable or metastatic ESCC, potentially accelerating its pathway to market.
AstraZeneca's IMblaze 410 trial investigating Imfinzi (durvalumab) in combination with chemotherapy met its primary endpoint, showing improved overall survival in patients with stage III resectable ESCC after surgery.
Seagen secures Fast Track designation from the US FDA for tucatinib (a HER2 tyrosine kinase inhibitor) in combination with other standard therapies for advanced ESCC with HER2 alterations.
Eli Lilly and Innovent Biologics form a strategic partnership to develop and commercialize innovative therapies for ESCC and other cancers. This collaboration combines their expertise and resources to accelerate drug development and market access.
Bristol-Myers Squibb and Checkmate Pharmaceuticals agree to co-develop and commercialize OPB-838, a novel drug candidate with potential for ESCC treatment, leveraging their combined strengths in clinical development and commercialization.
Esophageal Squamous Cell Carcinoma Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)